BioSpace News Archive

Tabula Rasa HealthCare, Inc®, a leading healthcare technology company advancing the safe use of medications, announced it has partnered with OneOme, co-founded by Mayo Clinic, a provider of solutions for implementing pharmacogenomics in patient care to advance more optimal patient outcomes.

ERT, the global leader in clinical endpoint data collection, today announced new features and functionality for their industry-leading MasterScopeTM Pulmonary Function Testing (PFT) platform, which enables greater safety and ease of use for both patients and test administrators, as well as the collection of higher quality data.

Results in new study showed INO-4800 vaccine-induced neutralizing antibodies and T cell responses against UK, South African and Brazilian variant strains

Soliton, Inc., (Nasdaq: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted its special 510(k) application previously submitted on March 31, 2021 for modifications to RESONIC ™ device

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2021 on Thursday, April 29, 2021, before the U.S. financial markets open.

Abiomed (NASDAQ:ABMD) announced today that the first patient has been enrolled in PROTECT IV, a large, prospective, multi-center randomized controlled trial (RCT) that is designed to provide the level of clinical evidence needed to achieve a Class I guideline recommendation for Impella in high-risk percutaneous coronary intervention (HRPCI).

Prof Pascal Defaye of CHU de Grenoble-Alpes performed world first Leadless LBBAP implant

Tallac Therapeutics, Inc. (“Tallac”), a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, today announced the appointment of Curtis Hecht as Chief Business Officer

Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today reported that more than 100 accounts have purchased Pantheris SV OCT-guided atherectomy catheters for the treatment of PAD since product launch in the third quarter of 2019.

InterVenn Biosciences today announced that Padmanee Sharma, MD, PhD, has joined the Company’s Board of Advisors, effective March 9, 2021. Dr. Sharma joins the InterVenn Board of Advisors with extensive experience in basic and clinical immunology and cancer research.